Conley Chee - 15 Feb 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Commercial Officer
Signature
/s/ Gerald E. Quirk, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
15 Feb 2022
Net transactions value
$0
Form type
4
Filing time
17 Feb 2022, 15:09:39 UTC
Previous filing
28 Sep 2021
Next filing
11 Oct 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 15 Feb 2022 Common Stock 100,000 $1.59 Direct F1
transaction SYRS Restricted Stock Units Award $0 +80,000 $0.000000 80,000 15 Feb 2022 Common Stock 80,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option becomes exercisable as to one quarter (1/4th) of the shares on February 28, 2023, with the remainder vesting in monthly installments equal to one forty-eighth (1/48th) of the original number of shares at the end of each of the next thirty-six (36) months thereafter.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3 These RSUs will vest in four equal annual installments commencing on March 31, 2023.